Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Neurophth Therapeutics
company
About
Neurophth is China's first gene therapy company for ophthalmic diseases.
- 251 - 500
Details
- Last Funding Type
- Angel
- Industries
- Biotechnology,Life Science
- Founded date
- Jul 1, 2016
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥130M
Neurophth Therapeutics has raised a total of
¥130M
in funding over 2 rounds. Their latest funding was raised on
Apr 8, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 8, 2020 | Series A | ¥130M | 1 |
Fosun International
|
— | Detail |
| Jan 1, 2018 | Angel | — | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Neurophth Therapeutics is funded by 2 investors.
Fosun International
and Qiji Zhiguang Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Fosun International
|
Yes | Series A |
|
|
Yes | Angel |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
